Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations

Medtronic plc (MDT) is gaining momentum, particularly in its Diabetes and Cardiovascular divisions, despite some mixed analyst ratings. Truist analyst Richard Newitter maintained a Hold rating but lowered the price target to $103, while Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target to $118, citing a solid third-quarter earnings beat. The company, which is a healthcare technology firm specializing in device-based medical therapies, is recognized by hedge funds as one of the top healthcare equipment stocks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)